AFP and hepatocellular carcinoma: In particular, through the controlled placebo study “REACH-2” [30], it has been found that, in a subgroup of patients with HCC having alpha-fetoprotein levels (AFP) of at least 400 ng/mL, the administration of ramucirumab led to an improvement in terms of OS and progression free survival (PFS) [31].